Table 12.12
Adjusted Patient Survival, Deceased Donor Lung Transplants
Survival at 3 Months, 1 Year, 3 Years, and 5 Years

	3 Months			1 Year			3 Years			5 Years		
	(Tx 2003 - 2004)			(Tx 2003 - 2004)			(Tx 2001 - 2004)			(Tx 1999 - 2004)		
	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.
Total												
All	2,151	93.5%	0.5%	2,151	85.3%	0.8%	4,161	66.4%	0.9%	5,925	50.9%	0.9%
Age at Tx												
<1 Year	8	53.9%	23.1%	8	53.9%	23.1%	13	59.1%	13.7%	20	68.6%	10.6%
1-5 Years	3	79.9%	15.2%	3	79.9%	15.2%	11	69.8%	14.3%	17	52.4%	13.8%
6-10 Years	15	94.5%	5.3%	15	88.8%	8.0%	27	76.1%	10.0%	44	65.6%	9.2%
11-17 Years	58	95.1%	2.8%	58	85.3%	5.0%	98	58.9%	6.7%	142	47.4%	5.9%
18-34 Years	285	93.5%	1.7%	285	85.6%	2.9%	533	62.6%	3.5%	759	49.3%	3.3%
35-49 Years	397	95.2%	1.0%	397	89.0%	1.5%	847	70.8%	1.8%	1,266	56.3%	1.9%
50-64 Years	1,230	93.0%	0.8%	1,230	84.7%	1.2%	2,398	66.5%	1.3%	3,373	49.7%	1.4%
65+ Years	157	92.8%	2.0%	157	78.8%	3.3%	238	59.7%	4.2%	308	42.9%	4.5%
Recipient Ethnicity/Race												
White	1,859	93.5%	0.6%	1,859	85.1%	0.8%	3,645	66.3%	0.9%	5,230	51.2%	1.0%
African American	157	95.0%	1.6%	157	86.6%	2.6%	302	68.6%	3.3%	418	46.8%	3.7%
Hispanic/Latino	99	91.0%	2.6%	99	83.4%	3.5%	158	60.9%	4.7%	207	52.2%	4.8%
Asian	26	97.1%	2.8%	26	94.2%	3.9%	40	82.7%	6.0%	47	60.8%	11.0%
Other/Multi-race	8	89.3%	9.4%	8	89.3%	9.4%	14	73.7%	10.8%	21	37.9%	13.1%
Unknown	2	+	+	2	+	+	2	+	+	2	+	+
Recipient Gender												
Female	1,032	93.4%	0.8%	1,032	84.9%	1.1%	2,071	65.3%	1.3%	2,949	50.6%	1.3%
Male	1,119	93.6%	0.7%	1,119	85.6%	1.1%	2,090	67.8%	1.2%	2,976	51.2%	1.3%

Source: OPTN/SRTR Data as of May 1, 2006.

Notes:

(+) = Values not determined due to insufficient follow-up. (-) = Values not determined since there were no transplants in the category.

Cohorts are transplants performed during the years listed at the top of the table.

Patient survival follows patients from first transplant of this type until death. Counts for patient and graft survival are different because a patient may have more than one transplant for a type of organ.

Center volume = Center's yearly transplants performed during the base period, based on lung and heart-lung transplants.

Multi-organ transplants are excluded.

Survival rates are adjusted to the characteristics of the 3 month and 1 year cohort. See Technical Notes for details.

Table 12.12 (Continued)
Adjusted Patient Survival, Deceased Donor Lung Transplants
Survival at 3 Months, 1 Year, 3 Years, and 5 Years

	3 Months			1 Year			3 Years			5 Years		
	(Tx 2003 - 2004)			(Tx 2003 - 2004)			(Tx 2001 - 2004)			(Tx 1999 - 2004)		
	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.
Total												
All	2,151	93.5%	0.5%	2,151	85.3%	0.8%	4,161	66.4%	0.9%	5,925	50.9%	0.9%
Primary Diagnosis												
Emphysema/COPD	839	94.9%	0.8%	839	88.2%	1.2%	1,705	69.7%	1.4%	2,483	51.9%	1.5%
Cystic Fibrosis	348	94.7%	1.4%	348	84.8%	2.5%	649	67.5%	2.7%	941	51.1%	2.7%
Idiopathic Pulmonary Fibrosis	504	91.3%	1.3%	504	80.7%	1.8%	870	61.5%	2.1%	1,149	47.6%	2.2%
Alpha-1-Antitrypsin Deficiency	118	94.0%	2.2%	118	91.4%	2.6%	278	69.3%	3.2%	412	54.6%	3.4%
Primary Pulmonary Hypertension	74	81.2%	4.7%	74	77.0%	5.1%	155	62.6%	4.4%	230	53.6%	4.2%
Congenital Disease	17	100.0%	0.0%	17	87.1%	8.3%	33	58.5%	10.5%	61	47.8%	7.9%
Other	229	93.2%	1.7%	229	81.3%	2.7%	448	63.7%	2.8%	623	54.7%	2.6%
Unknown	22	81.8%	8.0%	22	72.8%	9.3%	23	69.6%	9.3%	26	69.1%	8.8%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
(+) = Values not determined due to insufficient follow-up. (-) = Values not determined since there were no transplants in the category.
Cohorts are transplants performed during the years listed at the top of the table.
Patient survival follows patients from first transplant of this type until death. Counts for patient and graft survival are different because a patient may have more than one transplant for a type of organ.
Center volume = Center's yearly transplants performed during the base period, based on lung and heart-lung transplants.
Multi-organ transplants are excluded.
Survival rates are adjusted to the characteristics of the 3 month and 1 year cohort. See Technical Notes for details.